SeaSpine Up +8% in 2Q19 on New Product Launches


SeaSpine leveraged newer spine and biologics products to grow in the high single digits amid increased case volume in 2Q19.

Increased 2019 revenue guidance by $1MM at both the high and low ends, bringing range to $155MM to $157MM
Case volume increased by about 10%, but was somewhat offset by low single-digit price decline...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Mike Evers is a Senior Market Analyst and writer with over 15 years of experience in the medical industry, spanning cardiac rhythm management, ER coding and billing, and orthopedics. He joined ORTHOWORLD in 2018, where he provides market analysis and editorial coverage.

Contact Us